Biofrontera Inc. (BFRI)

Market Cap	12.58M
Revenue (ttm)	29.05M
Net Income (ttm)	-22.67M
Shares Out	1.37M
EPS (ttm)	-17.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,956
Open	8.60
Previous Close	8.55
Day's Range	8.60 - 9.20
52-Week Range	7.40 - 25.80
Beta	n/a
Analysts	Strong Buy
Price Target	79.00 (+758.7%)
Earnings Date	Nov 13, 2023

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Oct 29, 2021
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: BFRI

Financial Performance

In 2022, Biofrontera's revenue was $28.67 million, an increase of 18.98% compared to the previous year's $24.10 million. Losses were -$640,000, -98.30% less than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for BFRI stock is "Strong Buy." The 12-month stock price forecast is $79.0, which is an increase of 758.70% from the latest price.

Price Target

$79.0

(758.70% upside)

Analyst Consensus: Strong Buy